28-Mar-2024
Bristol Myers Squibb (NYSE:BMY) Slips after Disappointing Drug Trial
TipRanks (Thu, 28-Mar 5:20 PM ET)
Bristol Myers drug Zeposia fails Phase 3 study for Crohn's disease
Seeking Alpha News (Thu, 28-Mar 4:39 PM ET)
Business Wire (Thu, 28-Mar 4:05 PM ET)
Business Wire (Thu, 28-Mar 4:01 PM ET)
Globe Newswire (Thu, 28-Mar 7:30 AM ET)
PRNewswire (Wed, 27-Mar 7:53 PM ET)
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
Benzinga (Wed, 27-Mar 9:20 AM ET)
BTIG upgrades Nuvation to buy, cites AnHeart acquisition
Seeking Alpha News (Tue, 26-Mar 1:37 PM ET)
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Business Wire (Tue, 26-Mar 6:59 AM ET)
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.
As of March 28, 2024, BMY stock price climbed to $54.23 with 12,117,622 million shares trading.
BMY has a beta of 0.37, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.05 to the broad based SPY ETF.
BMY has a market cap of $109.66 billion. This is considered a Large Cap stock.
Last quarter Bristol-Myers Squibb Company reported $11 billion in Revenue and $1.70 earnings per share. This beat revenue expectation by $285 million and exceeded earnings estimates by $.17.
In the last 3 years, BMY stock traded as high as $81.44 and as low as $47.58.
The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, VOO, SCHD, SPY, IVV.
BMY has underperformed the market in the last year with a return of -16.9%, while the SPY ETF gained +33.6%. In the last 3 month period, BMY fell short of the market, returning +7.1%, while SPY returned +10.1%. However, in the most recent 2 weeks BMY has outperformed the stock market by returning +3.0%, while SPY returned +1.7%.
BMY support price is $52.53 and resistance is $53.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY stock will trade within this expected range on the day.